Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 8931-230
Fax: +49 (0)711 - 8931-323
send an Email


Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2011: 105/4 (Apr) pp. 571-741
Pages: 721-729

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

A randomised, double-blind, non-inferiority trial

Online Supplementary Material

B. I. Eriksson (1), O. E. Dahl (2), M. H. Huo (3), A. A. Kurth (4), S. Hantel (5), K. Hermansson (6), J. M. Schnee (7), R. J. Friedman (8), for the RE-NOVATE II Study Group

(1) University of Gothenburg, Department of Orthopaedics, Sahlgrenska University Hospital, Mölndal, Sweden; (2) Elverum Central Hospital, Norway; (3) Department of Orthopedic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, USA; (4) Department of Orthopaedic Surgery, University Medical Centre, Mainz, Germany; (5) Medical Data Services, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; (6) Medical Department, Boehringer Ingelheim AB, Stockholm, Sweden; (7) Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA; (8) Medical University of South Carolina and Charleston Orthopaedic Associates, Charleston, South Carolina, USA


venous thromboembolism, prophylaxis, oral anticoagulant, dabigatran etexilate, Total hip arthroplasty


This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embolism) plus VTE-related death. The main safety outcome was major bleeding. In total, 2,013 were treated, of whom 1,577 operated patients were included in the primary efficacy analysis. The primary efficacy outcome occurred in 7.7% of the dabigatran group versus 8.8% of the enoxaparin group, risk difference (RD) –1.1% (95%CI –3.8 to 1.6%); p<0.0001 for the pre-specified non-inferiority margin. Major VTE plus VTE-related death occurred in 2.2% of the dabigatran group versus 4.2% of the enoxaparin group, RD –1.9% (-3.6% to –0.2%); p=0.03. Major bleeding occurred in 1.4% of the dabigatran group and 0.9% of the enoxaparin group (p=0.40). The incidence of adverse events, including liver enzyme elevations and cardiac events, during treatment was similar between the groups. Extended prophylaxis with oral dabigatran 220 mg once-daily was as effective as subcutaneous enoxaparin 40 mg once-daily in reducing the risk of VTE after total hip arthroplasty, and superior to enoxaparin for reducing the risk of major VTE. The risk of bleeding and safety profiles were similar.

You may also be interested in...


D. Bergqvist (1), J. I. Arcelus (2), P. Felicissimo (3), ETHOS investigators

Thromb Haemost 2012 107 2: 270-279

Manuel Monreal 1, Luis Peidro 2, Carlos Resines 3, Carlos Garcés 4, José Luís Fernández 5, Eduardo Garagorri 6, Juan Carlos González 7, for the NETCOT Investigators*

Thromb Haemost 2008 99 6: 1112-1115

A. Kurth

arthritis + rheuma 2007 27 6: 345-350